or Try an Advanced Search...

    Technical Analysis for ALLK - Allakos Inc.

    Grade Last Price % Change Price Change
    C 1.35 -4.26% -0.06
    ALLK closed down 4.26 percent on Thursday, November 7, 2024, on 41 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Up
    Historical ALLK trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Stochastic Reached Overbought Strength -4.26%
    Wide Bands Range Expansion -4.26%
    Overbought Stochastic Strength -4.26%
    Gapped Down Weakness -4.26%
    180 Bullish Setup Bullish Swing Setup -0.74%
    Wide Bands Range Expansion -0.74%
    Wide Bands Range Expansion 8.00%
    Older End-of-Day Signals for ALLK ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 5 hours ago
    Possible Inside Day about 5 hours ago
    Down 3% about 10 hours ago
    Down 2 % about 10 hours ago
    Down 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ALLK Chart by TradingView
    Basic chart:

    Profile

    Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mast Cell Mastocytosis Systemic Mastocytosis Eosinophil

    Is ALLK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 22 3 US Penny Stocks With Market Caps Larger Than $50M
    Oct 10 Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
    Aug 8 Allakos GAAP EPS of -$0.30
    Aug 7 Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
    Jul 23 Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?
    Jun 26 Allakos drops after early-stage results for lead asset
    May 28 Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
    May 10 Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
    May 9 Allakos GAAP EPS of -$0.81 misses by $0.37
    May 9 Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
    See more ALLK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.405
    52 Week Low 0.535
    Average Volume 679,351
    200-Day Moving Average 1.04
    50-Day Moving Average 0.80
    20-Day Moving Average 1.07
    10-Day Moving Average 1.30
    Average True Range 0.14
    RSI (14) 67.11
    ADX 59.16
    +DI 31.76
    -DI 3.53
    Chandelier Exit (Long, 3 ATRs) 1.06
    Chandelier Exit (Short, 3 ATRs) 1.05
    Upper Bollinger Bands 1.65
    Lower Bollinger Band 0.48
    Percent B (%b) 0.74
    BandWidth 109.42
    MACD Line 0.18
    MACD Signal Line 0.16
    MACD Histogram 0.0192
    Fundamentals Value
    Market Cap 118.09 Million
    Num Shares 87.5 Million
    EPS -1.53
    Price-to-Earnings (P/E) Ratio -0.88
    Price-to-Sales 0.00
    Price-to-Book 0.53
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.54
    Resistance 3 (R3) 1.56 1.50 1.51
    Resistance 2 (R2) 1.50 1.45 1.50 1.50
    Resistance 1 (R1) 1.43 1.42 1.40 1.41 1.49
    Pivot Point 1.37 1.37 1.36 1.37 1.37
    Support 1 (S1) 1.30 1.32 1.27 1.29 1.21
    Support 2 (S2) 1.24 1.29 1.24 1.20
    Support 3 (S3) 1.17 1.24 1.19
    Support 4 (S4) 1.16